ClinicalTrials.gg
DrugBiological

Nadofaragene firadenovec clinical trials

Also written SCH 721015, INSTILADRIN and rAd-IFN.

studies test it
15
open now
6
in phase 3
6
first study started
2006

How each study uses nadofaragene firadenovec is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the nadofaragene firadenovec studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
16 Dec 2022 · Adstiladrin · BLA 125700 (FDA, Purple Book)
European Union
28 May 2026 · Adstiladrin · EMEA/H/C/005856 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Nadofaragene Firadenovec
8
Adstiladrin
6

Brand

INSTILADRIN
3

Development codes

SCH 721015
5
rAd-IFN
2
FE 999326
1
TR-002
1

Studies by the year they started

15 studies that test it; most in 2024 (3)

Studies that test nadofaragene firadenovec, by start year
YearStudies
20061
20091
20101
20111
20121
20161
20191
20221
20243
20253
20261

By phase

A phase 1/2 study counts in both.

Phase 1
6
Phase 2
3
Phase 3
6
Phase 4
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 8 · Other 7

Ferring Pharmaceuticals (6) · Abramson Cancer Center at Penn Medicine (2) · Ferring Ventures Limited (1) · University of Pennsylvania (1) · FKD Therapies Oy (1) · M.D. Anderson Cancer Center (1) · University of Washington (1) · Memorial Sloan Kettering Cancer Center (1)

Often tested with

Tested in the same studies.

Gemcitabine (1) · Docetaxel (1) · Pembrolizumab (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test nadofaragene firadenovec.

Studies

Open first, then newest update. How each study uses nadofaragene firadenovec is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 15

Codes

What other systems call nadofaragene firadenovec · ClinicalTrials.gg INT002127

  • MeSH (NLM) C000731690nadofaragene firadenovecOne source NLM
  • UNII (FDA) 0OOS09O1FHNADOFARAGENE FIRADENOVECConfirmed FDA, NLM
  • NCI Thesaurus C71011Nadofaragene FiradenovecOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.